Abstract
Background: Guselkumab (GUS) is effective in treating moderate to severe psoriasis. Here, we characterized the baseline profile of patients with moderate to severe psoriasis achieving superresponse (defined as patients who achieved a Psoriasis Severity and Area Index [PASI] 100 response at both weeks 20 and 28) with GUS treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
